PRESS-RELEASE ·Filed Mar 26, 2026
Press release: offering
Actionable Insight • Neutral
Monitor pipeline advancement, particularly phase progression of zumilokibart; assess whether capital raise supports extended runway without near-term dilution risk.
Final — all horizons settled through T+60d
APGE ▲ +70.66% at T+60d
NEUTRAL call ✓ call won +70.66% · α vs SPY +54.59% · entry $77.82 → $132.81
T+1d
+1.16%
call +1.16% · α +1.51%
$78.72
settled 6mo ago
T+5d
+7.95%
call +7.95% · α +4.09%
$84.01
settled 6mo ago
T+20d
+11.12%
call +11.12% · α -1.63%
$86.47
settled 5mo ago
T+60d
+70.66%
call +70.66% · α +54.59%
$132.81
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Apogee Therapeutics completed a public offering of 5,750,000 shares at $70.00 per share, raising approximately $403 million in gross proceeds. The capital will support development of its clinical-stage biologics pipeline in inflammatory and immunology indications.
Key Financial Metrics
Deal Value
$403.0M
Key Facts
- Apogee Therapeutics closed an underwritten public offering of 5,750,000 shares of common stock
- Offering price was $70.00 per share, with full exercise of underwriters' option for 750,000 additional shares
- Aggregate gross proceeds were approximately $403 million before expenses
- Proceeds will be used to advance clinical development of Apogee's biologics pipeline, including zumilokibart (APG777) for atopic dermatitis, asthma, and EoE
- Jefferies, TD Cowen, Stifel, and Guggenheim Securities acted as joint book-running managers
Financial Impact
$403 million in gross proceeds, dilutive to existing shareholders by approximately 5.75M shares
dilutioncashequity
Risk Factors
- Dilution to existing shareholders from issuance of new shares
- Execution risk in advancing clinical programs despite funding
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263384 |
31 reports for APGE
93% Hit rate best @ T+60▲ +73.31%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 15-12G | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 25-NSE | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | 8-K | $135.06 awaiting T+5 | awaiting T+5 | — | — |
Aug 11, 2026 7w ago | 8-K | $134.55 $134.71 | ▲ +0.12% | ▲ +0.56% | — |
Aug 10, 2026 7w ago | 8-K | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 10, 2026 7w ago | Press Release | $134.65 $134.59 | ▼ −0.04% | ▲ +0.00% | — |
Aug 6, 2026 8w ago | Institutional Cluster | $134.49 $134.45 | ▼ −0.03% | ▼ −1.24% | — |
Aug 3, 2026 8w ago | DEFA14A | $134.19 $134.69 | ▲ +0.37% | ▲ +0.47% | — |
Jul 11, 2026 11w ago | Insider Cluster | $133.82 $134.00 | ▲ +0.13% | ▲ +0.92% | — |
Jun 26, 2026 13w ago | DEFA14A | $132.61 $133.50 | ▲ +0.67% | ▼ −0.72% | — |
Showing 10 of 31
US Market Status
Market Open — Closes in 52m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access